Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.

Hepatology (Baltimore, Md.) - 1 Sept 2013

Herraez Elisa, Lozano Elisa, Macias Rocio I R, Vaquero Javier, Bujanda Luis, Banales Jesus M, Marin Jose J G, Briz Oscar

Abstract excerpt

UNLABELLED: Reduced drug uptake is an important mechanism of chemoresistance. Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug. Here we investigated whether SLC22A1 variants may contribute to sorafenib chemoresistance. Complete sequencing and selective variant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Niacinamide

Share to Organic Cation Transporter 1

Share to Phenylurea Compounds

Share to Sorafenib

Share to Xenopus laevis

Source

Identifiers

PMID: 23532667
DOI: 10.1002/hep.26425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.PMID 23532667Read ↗

Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.Semantic proximity Read ↗

The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomicsSemantic proximity Read ↗

Epigenetic events involved in organic cation transporter 1‐dependent impaired response of hepatocellular carcinoma to sorafenibSemantic proximity Read ↗

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinomaSemantic proximity Read ↗

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.Semantic proximity Read ↗

The Effect of Single Nucleotide Variations in the Transmembrane Domain of OATP1B1 on in vitro Functionality.Semantic proximity Read ↗

PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2).Semantic proximity Read ↗

The human organic cation transporter OCT1 and its role as a target for drug responsesSemantic proximity Read ↗

Genetic Heterogeneity of SLC22 Family of Transporters in Drug DispositionSemantic proximity Read ↗

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Semantic proximity Read ↗

In vitro characterization of SLCO2B1 genetic variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.